Malfitano Anna Maria, Di Somma Sarah, Prevete Nella, Portella Giuseppe
Dipartimento di Scienze Mediche Traslazionali, Università Federico II Napoli, URT "Genomic of Diabetes" of Institute of Experimental Endocrinology and Oncology "G. Salvatore", National Council of Research (CNR), 80131 Naples, Italy.
Cancers (Basel). 2020 Jan 23;12(2):281. doi: 10.3390/cancers12020281.
Our work is focused on the future clinical use of oncolytic viruses (OVs) for the treatment of aggressive thyroid carcinomas. Therefore, we provide a brief description of the overall use of OVs in the clinic. Rigvir is among the few OVs that have already been used for the treatment of patients, and studies describing its effects have been briefly commented and cited in our text [1]. [...].
我们的工作聚焦于溶瘤病毒(OVs)在侵袭性甲状腺癌治疗中的未来临床应用。因此,我们简要介绍了OVs在临床上的整体应用情况。Rigvir是少数几种已用于治疗患者的OVs之一,我们在文中对描述其效果的研究进行了简要评论并引用[1]。[...]